Pneumococcal Vaccination for a 69-Year-Old
A 69-year-old should receive a single dose of pneumococcal vaccine now if they have never received one, with the choice between PCV20 alone OR PCV15 followed by PPSV23 at least 1 year later. 1
Current ACIP Recommendations (2024-2025)
The most recent guidelines from ACIP now recommend pneumococcal vaccination for all adults aged ≥50 years who have never received a pneumococcal conjugate vaccine (PCV) 1, 2. At age 69, this patient falls well within the universal vaccination age group.
For Previously Unvaccinated Adults ≥65 Years
Two acceptable vaccination schedules exist 3:
Schedule Option A (Single-dose approach):
- Administer one dose of PCV20 (or PCV21)
- No additional doses needed
Schedule Option B (Two-dose approach):
- Administer PCV15 first
- Follow with PPSV23 at least 1 year later (for immunocompetent adults)
- If immunocompromised, CSF leak, or cochlear implant: give PPSV23 after ≥8 weeks instead 3
If Previously Vaccinated
The recommendation depends on what vaccine(s) were received previously 3:
If received PPSV23 only:
- Give PCV20 (or PCV15) at least 1 year after the last PPSV23 dose
- If PCV15 is chosen, follow with PPSV23 ≥1 year later
If received PCV13 only:
- Give PCV20 at least 1 year after PCV13
- OR give PPSV23 at least 1 year after PCV13 (≥8 weeks if immunocompromised)
If received both PCV13 and PPSV23 before age 65:
- Give one dose of PPSV23 at age ≥65 years, at least 5 years after the previous PPSV23 dose
- OR consider PCV20 after ≥5 years from last dose (shared decision-making)
If received both PCV13 and PPSV23 at age ≥65:
- No additional doses routinely needed
- May consider PCV20 after ≥5 years through shared decision-making 3
Key Changes from Previous Guidelines
The 2019 ACIP update eliminated the routine recommendation for PCV13 in all adults ≥65 years, moving instead to "shared clinical decision-making" for immunocompetent adults 4. However, the 2024 guidelines have simplified this by recommending PCV for all adults ≥50 years who are PCV-naïve 1, 2.
Critical Point About Immunocompromising Conditions
If the patient has any of these conditions, the timing between vaccines shortens to ≥8 weeks 3:
- Chronic renal failure
- Asplenia (functional or anatomic)
- Immunodeficiencies (B-cell, T-cell, complement, phagocytic disorders)
- Malignancy
- HIV infection
- Immunosuppressive therapy (including long-term corticosteroids)
- Sickle cell disease
- Solid organ transplant
- CSF leak or cochlear implant
Important Implementation Notes
No additional PPSV23 doses after age 65: Once a patient receives PPSV23 at age ≥65 years, no further PPSV23 doses should be given 4. This is a firm stopping point.
Vaccine spacing matters: PCV13 and PPSV23 (or any pneumococcal vaccines) should never be coadministered on the same day 4.
Self-reported vaccination history is acceptable for determining prior doses 1.
Common Pitfalls to Avoid
Don't give multiple PPSV23 doses after age 65 - this is explicitly not recommended and provides no additional benefit 4
Don't forget the 5-year interval - if the patient received PPSV23 before age 65, they need at least 5 years before the next PPSV23 dose at age ≥65 4
Check immunization registries - up to 22% of vaccinations may be missed if only checking the health system's electronic records 5
Consider the simpler single-dose option - PCV20 or PCV21 alone eliminates the need for follow-up and improves completion rates, which historically have been poor (only 17% full compliance in real-world data) 6, 7
The evidence strongly supports pneumococcal vaccination at this age to reduce morbidity and mortality from invasive pneumococcal disease and pneumonia 4, 8.